Advertisement #1
Home Clinical development Phase II

Phase II

Phase II

Improving Clinical Trials with a Simpler and More Inclusive Study Design

Editorial Team -

Combination of Olaparib + Ceralasertib Offers Clinical Benefit in DNA Repair-deficient Tumors

Editorial Team -

Sudocetaxel Zendusortide Shows Potential as a Single Agent and as a Combination Therapy

Editorial Team -

Study Shows Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104

Editorial Team -

REGN5459 Shows Encouraging Clinical Activity in Patients With r/r Multiple Myeloma

Editorial Team -

L-MIND Study Shows Prolonged, Durable Responses in r/r DLBCL Patients Treated with Tafasitamab

Editorial Team -

Patients with Rare Type of Skin Cancer May Benefit from Single-agent Pembrolizumab

Editorial Team -

Zolbetuximab Plus CAPOX Improves Survival in Select Gastric Cancers

Editorial Team -

FDA Priority Review of NDA for Nirogacestat for the Treatment of Rare Desmoid Tumors

Editorial Team -

Sermonix and Quantum Leap Evaluate Lasofoxifene in New Study Arm of Ongoing I-SPY 2...

Editorial Team -
123...6Page 1 of 6

LATEST NEWS

Advertisment #12
© 2001 - 2023 Sunvalley Communication, LLC. All Rights Reserved.

X